Forxiga approved in Europe for type 1 diabetes mellitus


25 March 2019 - Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type 1 diabetes and the first AstraZeneca medicine ever approved for type 1 diabetes.

The European Commission has approved Forxiga (dapagliflozin) for use in type 1 diabetes (T1D) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. This is the first approval of Forxiga for the treatment of patients with T1D.

The approval is based on data from the Phase III DEPICT clinical programme for Forxiga in T1D.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Australia